- Dr. Iannello brings cross-disciplinary and licensing skills to build traction for Gordagen's diverse portfolio
- Cardiologist and Associate Professor, David Prior, to join Scientific Advisory Board to assist in development of Hyperlipidemia prescription product
MELBOURNE, Australia, July 17, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Dr. Rocco Iannello as Director of Business Development.
Dr. Iannello will be responsible for Gordagen's business development, including major international licensing and partnering deals for Gordagen's prescription and over-the-counter product portfolio. As a seasoned biotechnology commercialization professional, Dr. Iannello has overseen significant transactions in the pharmaceuticals industry and has a proven ability to build research alliances and out-licensing opportunities between industry and academia.
"We are pleased to have Dr. Iannello as part of the Gordagen team as we begin to commercialize our growing tocotrienol-based product portfolio," commented Dr. Glenn Tong, CEO and Managing Director of Gordagen Pharmaceuticals.
"He has a proven ability to manage the interests and commercial imperatives of multiple parties with diverse agendas and has achieved exceptional commercial outcomes. We believe his understanding of the different drivers, players and requirements for both prescription and non-prescription products will be a tremendous asset to Gordagen. We look forward to his contributions in building long-term value for the Company and its stakeholders."
Dr. Iannello was most recently Director Business Development for Monash Institute of Pharmaceutical Sciences, working with the Faculty of Medicine, Nursing and Health Sciences and the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia, where he has been involved across numerous high value commercial transactions involving partners such as GlaxoSmithKline, Servier, Takeda, and Capsugel. He was also involved in the formation of a number of spin-out biotechnology companies.
In his previous roles, Dr. Iannello was responsible for implementation of licensing strategies and commercialization deals across multiple parties, as well as complex contract negotiations. In the past, he has served as non-executive director of several companies, including as a founding director of Paranta Biosciences and CRC Biomedical Imaging Development.
"With the planned launch of Gordagen's first product for early next year, and a strong rollout of the portfolio across a range of indications, business development will be an integral component to achieving the Company's goals. I am excited to be working with such an experienced team and helping to build a strong marketing and distribution platform as we seek to ensure Gordagen's long-term success," said Dr. Rocco Iannello.
Gordagen also announced that cardiologist Associate Professor David Prior has joined the Scientific Advisory Board as a specialist advisor. A/Prof. Prior is currently Deputy Director of Cardiology and Director of Non-invasive Cardiac Imaging at St Vincent's Hospital in Melbourne, and will assist Gordagen with its heart health, exercise endurance and hyperlipidemia clinical and product development programs, providing significant guidance to clinical unmet needs and current approaches. One of his focus areas is on the effects of endurance exercise on cardiac function and mechanisms of cardiac dysfunction following extreme exercise, which will be of significant benefit to Gordagen.
About Gordagen Pharmaceuticals Pty Ltd
Gordagen Pharmaceuticals is a privately-held Australian company developing and commercialising evidence-based prescription medicines and nutraceuticals based on natural tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patented MELT3 delivery technology. The Company is focusing on tocotrienols with wide therapeutic potential, for the treatment of heart health, muscle soreness and exercise endurance and a range of indications with unmet medical needs (ie. Hyperlipidemia, hypertension and diabetes) www.gordagen.com.
CONTACT: Inquiries: Dr. Glenn Tong, Managing Director and CEO Ph: +61 (0) 412 193 350 Investor and Media Inquiries: Paris Brooke - Australia and Asia Ph: +61 (0) 407 715 574 David Burke, The Ruth Group - Americas, Europe Ph: +1 646 536-7009Source:Gordagen Pharmaceuticals